CD70 and neoplasm: In addition, cusatuzumab directly kills CD70‐expressing tumour cells through enhanced antibody‐dependent cell‐mediated phagocytosis (ADCP), complement‐dependent cytotoxicity (CDC), and antibody‐dependent cell‐mediated cytotoxicity (ADCC).55